glp-1 drugs review The New The GLP-1 Agonists and Obesity:

Question 4: what other conditions besides obesity may contribute to the development of hepatic steatosis

Dr Amit Srivastava Weight Loss Specialist UK 3 min read In recent years, the landscape of weight management has rapidly evolved, especially for women navigating midlife hormonal changes

The introduction of insulin in type 2 diabetes mellitus

Current Opinion in Rheumatology

doi: 10.3389/fendo.2019.00389 Received 07 April 2019 Accepted 30 May 2019 Published 19 June 2019 Volume 10 - 2019 Edited by Jens Juul Holst, University of Copenhagen, Denmark Reviewed by Leon Bach, Monash University, Australia

One article found an increased incidence of aspiration pneumonia among GLP-1 users compared to non-users reporting a hazard ratio of 1.33 (95%CI 1.021.74, p = 0.036) (Australian Diabetes Society, National Association of Clinical Obesity Services, Gastroenterological Society of Australia, and Australian and New Zealand College of Anaesthetists n.d.)